Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health

Aurora García-Rendón, Adriana Garibay-Escobar, Roberto Guzmán, Armando Tejeda-Mansir

Resultado de la investigación: Capítulo del libro/informe/acta de congresoCapítulorevisión exhaustiva

5 Citas (Scopus)

Resumen

One of the most important applications of immunology has been the production of various types of vaccines. Currently, new plasmid DNA (pDNA) vaccines are been developed, given rise to more cost-effective and clean production processes. These processes involve the upstream and downstream stages to produce, isolate, and purify the pDNA. The effectiveness of pDNA vaccines against pathogen microorganisms and cancer cells has been demonstrated in clinical assays and in commercial veterinary vaccines. However, low transfection efficiency and brief transgene expression have been attained in some trials. The use of cationic lipid-based nanoparticles to avoid these problems is an alternative approach that has been tested clinically. This chapter provides a summary of the advances and major challenges associated with the fusion of pDNA production technology and nanoparticle delivery technologies to produce pDNA lipid nanovaccines.

Idioma originalInglés
Título de la publicación alojadaLipid Nanocarriers for Drug Targeting
EditorialElsevier
Páginas231-267
Número de páginas37
ISBN (versión digital)9780128136874
ISBN (versión impresa)9780128136881
DOI
EstadoPublicada - 1 ene 2018

Nota bibliográfica

Publisher Copyright:
© 2018 Elsevier Inc. All rights reserved.

Huella

Profundice en los temas de investigación de 'Plasmid-DNA lipid nanovaccines: An innovative approach for a better world health'. En conjunto forman una huella única.

Citar esto